116 related articles for article (PubMed ID: 11891530)
21. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma.
Broecker-Preuss M; Sheu SY; Worm K; Feldkamp J; Witte J; Scherbaum WA; Mann K; Schmid KW; Schott M
Horm Metab Res; 2008 Oct; 40(10):685-91. PubMed ID: 18622894
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 protein expression in human thyroid gland and thyroid cancer.
Temmim L; Ebraheem AK; Baker H; Sinowatz F
Anat Histol Embryol; 2006 Apr; 35(2):125-9. PubMed ID: 16542178
[TBL] [Abstract][Full Text] [Related]
23. Regulation of p57(KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation.
Figliola R; Busanello A; Vaccarello G; Maione R
J Mol Biol; 2008 Jul; 380(2):265-77. PubMed ID: 18513743
[TBL] [Abstract][Full Text] [Related]
24. Nucleophosmin is overexpressed in thyroid tumors.
Pianta A; Puppin C; Franzoni A; Fabbro D; Di Loreto C; Bulotta S; Deganuto M; Paron I; Tell G; Puxeddu E; Filetti S; Russo D; Damante G
Biochem Biophys Res Commun; 2010 Jul; 397(3):499-504. PubMed ID: 20515654
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of p57Kip2 induces prostate cancer in the mouse.
Jin RJ; Lho Y; Wang Y; Ao M; Revelo MP; Hayward SW; Wills ML; Logan SK; Zhang P; Matusik RJ
Cancer Res; 2008 May; 68(10):3601-8. PubMed ID: 18483241
[TBL] [Abstract][Full Text] [Related]
26. p57KIP2: "Kip"ing the cell under control.
Pateras IS; Apostolopoulou K; Niforou K; Kotsinas A; Gorgoulis VG
Mol Cancer Res; 2009 Dec; 7(12):1902-19. PubMed ID: 19934273
[TBL] [Abstract][Full Text] [Related]
27. TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57
Li X; Ruan X; Zhang P; Yu Y; Gao M; Yuan S; Zhao Z; Yang J; Zhao L
Oncogene; 2018 May; 37(21):2773-2792. PubMed ID: 29511350
[TBL] [Abstract][Full Text] [Related]
28. Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies.
Basolo F; Fiore L; Pollina L; Fontanini G; Conaldi PG; Toniolo A
Clin Cancer Res; 1998 Feb; 4(2):381-7. PubMed ID: 9516926
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer.
Chiappetta G; De Marco C; Quintiero A; Califano D; Gherardi S; Malanga D; Scrima M; Montero-Conde C; Cito L; Monaco M; Motti ML; Pasquinelli R; Agosti V; Robledo M; Fusco A; Viglietto G
Endocr Relat Cancer; 2007 Jun; 14(2):405-20. PubMed ID: 17639054
[TBL] [Abstract][Full Text] [Related]
30. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes.
Gosselet FP; Magnaldo T; Culerrier RM; Sarasin A; Ehrhart JC
Cell Signal; 2007 Apr; 19(4):731-9. PubMed ID: 17112701
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of cyclin-dependent kinase inhibitor; p57(kip2), is involved in the cell cycle progression of vascular smooth muscle cells.
Nakano N; Urasawa K; Takagi Y; Saito T; Kaneta S; Ishikawa S; Higashi H; Tsutsui H; Hatakeyama M; Kitabatake A
Biochem Biophys Res Commun; 2005 Dec; 338(3):1661-7. PubMed ID: 16259944
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
33. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.
Vlachos P; Nyman U; Hajji N; Joseph B
Cell Death Differ; 2007 Aug; 14(8):1497-507. PubMed ID: 17464323
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical study of glypican 3 in thyroid cancer.
Yamanaka K; Ito Y; Okuyama N; Noda K; Matsumoto H; Yoshida H; Miyauchi A; Capurro M; Filmus J; Miyoshi E
Oncology; 2007; 73(5-6):389-94. PubMed ID: 18511877
[TBL] [Abstract][Full Text] [Related]
35. OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview.
Ruangpratheep C; Lohachittranond C; Poonpracha T; Punyarit P
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S281-9. PubMed ID: 16858970
[TBL] [Abstract][Full Text] [Related]
36. p57(Kip2) and cancer: time for a critical appraisal.
Borriello A; Caldarelli I; Bencivenga D; Criscuolo M; Cucciolla V; Tramontano A; Oliva A; Perrotta S; Della Ragione F
Mol Cancer Res; 2011 Oct; 9(10):1269-84. PubMed ID: 21816904
[TBL] [Abstract][Full Text] [Related]
37. Expression of the components of the Cip/Kip family in malignant lymphoma of the thyroid.
Ito Y; Yoshida H; Matsuzuka F; Matsuura N; Nakamura Y; Nakamine H; Kakudo K; Kuma K; Miyauchi A
Pathobiology; 2004; 71(3):164-70. PubMed ID: 15051930
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.
Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK
J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid.
Ito Y; Suzuki T; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Yamamoto T; Miyauchi A
Cancer Lett; 2005 Apr; 220(2):237-42. PubMed ID: 15766599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
